Table 2. Iodine-125 seed implantation for advanced pancreatic cancer.
| Author [year] | Cases | Guide | Seed | Median follow-up (mos) | Median survival (mos) | Severe complication | Survival (%) |
|
|---|---|---|---|---|---|---|---|---|
| 1-yr | 3-yr | |||||||
| Joyce [1990] (19) | 19 | US | 4.7 | |||||
| Montemaggi [1991] (20)* | Most of 254 | 60-100 Gy | 7.0 | |||||
| Schuricht [1998] (21) | 43 | Intraoperation | NA | 56 | 19 (2 yr) | |||
| Jin [2007] (22) | 22 | EUS | 10 seeds | 9.3 | 9.0 | 0 | ||
| Wang Y [2009] (23)** | NA | NA | 8.6 | |||||
| Wang J [2009] (24) | 14 | US | 120 Gy | 33.9 | 7.8 | |||
| Wang CF [2010] (25) | 31 | 8.0 | 0 | 56 | ||||
| Wang Y [2010] (26) | 31 | CT | 2–25 | 10.3 | ||||
| Xu [2009] (27) | 49 | US/CT | 34 | 18 | 16.2 | 0 | 63.1 | 9.5 |
*Iodine-125 implantation was associated with external radiation and chemotherapy; **iodine-125 implantation was associated with pancreatectomy and chemotherapy; US, ultrasound; NA, no data.